Study Guide – Evolve MUN (19th to 20th July)

United Nations Office on Drugs and Crime

1
 INDEX

Sr. No. Particulars Page No.

1 Letter from the Executive Board 3

2 About the Committee (UNODC)

2.1 Mandate and Functions of UNODC

3 About the Agenda

4 Understanding the Opioid Crisis

5 Role of Pharmaceutical Corporations

6 Influence on Prescription Practices

7 International Actions & Legal Frameworks

8 Challenges in Global Regulation

9 Role of UNODC and International Cooperation

10 Key Terms and Concepts

11 Recommended Readings

2
 Letter from the Executive Board
Dear Delegates,
It is with great enthusiasm and a deep sense of responsibility that we welcome you to the
United Nations Office on Drugs and Crime (UNODC) at the 3rd Edition of Evolve MUN.
We urge you to analyze the crisis holistically, identify regulatory gaps, corporate failings, and
systemic loopholes—and propose realistic, enforceable, and implementable strategies that
balance public health, accountability, and legal feasibility.
This study guide is not a complete manual; it is merely a foundation designed to help you
understand the scope and complexity of the issue. The true value you bring lies in your
independent research, your ability to apply facts to frameworks, and your understanding of
how international cooperation and national interest intersect.
Remember, the opioid crisis is not a hypothetical debate. It is a reflection of our global
systems—where health, profit, justice, and policy collide.
We are confident that this committee will witness substantive deliberations, well-reasoned
proposals, and collaborative diplomacy. We look forward to observing how you apply your
research, negotiation skills, and critical thinking to one of the most pressing international
challenges of our time.
Warm regards,
Devanshu Bhavsar
(Chairperson)
devanshubhavsar4@[Link]
Ronith Naik
(Research Analyst)
ronith5555@[Link]

3
 About the Committee
United Nations Office on Drugs and Crime (UNODC)
Started in 1997, the United Nations Office on Drugs and Crime works to make the world
safer from drugs, crime, terrorism and corruption.
It works in 150 countries, building networks of cooperation across borders and providing
reliable data and analysis. UNODC is also training judges, police officers and border officials
as well as healthcare and social workers to make communities safer and more resilient.
The UNODC in real-world settings serves an advisory and technical role, within the MUN, it
will function as a platform for delegates to propose comprehensive, cooperative, and
solution-oriented draft resolutions that reflect the committee’s mandate and ethical
responsibility
Mission:
1. Tackle the world drug problem:
It works to reduce the production, trafficking, and abuse of illicit drugs through
prevention, treatment, and international cooperation.
2. Fight organized crime:
It combats transnational criminal networks involved in human trafficking, drug
smuggling, and illegal arms trade.
3. Prevent and counter corruption:
UNODC supports countries in creating transparent systems and enforcing anti-corruption
laws under the UN Convention Against Corruption (UNCAC).
4. Prevent and counter terrorism:
It assists nations in building legal and institutional frameworks to effectively respond to
and prevent acts of terrorism.
5. Promote fair and effective criminal justice systems:
The agency helps strengthen legal systems to ensure access to justice, rule of law, and
protection of human rights.

4
 Mandate and Functions of UNODC
Operating under the guidance of the United Nations General Assembly and ECOSOC, its
mandate is rooted in major international legal instruments.
The Commission on Narcotic Drugs (CND) was established by Economic and Social Council
(ECOSOC) resolution 9(I) in 1946, to assist the ECOSOC in supervising the application of
the international drug control treaties. In 1991, the General Assembly (GA) expanded the
mandate of the CND to function as the governing body of UNODC (A/RES/46/104). The
CND's agenda has two distinct segments: a normative segment for discharging treaty-based
and normative functions; and an operational segment for exercising the role as the governing
body of UNODC.
UNODC is mandated to support the Member States in facing threats and impact of drugs and
crime. A number of conventions, treaties, and international instruments guide our work such
as;
The United Nations Convention against Transnational Organized Crime (UNTOC)
The United Nations Convention against Corruption (UNCAC)
Convention on Narcotic Drugs (1961)
Convention on Psychotropic Substances (1971)
Convention against the Illicit Traffic in Narcotic Drugs and Psycotropic Substances (1988)
The Compendium of UN standards and norms in crime prevention and criminal justice.
International legal framework against terrorism, including 19 international legal instruments.
General Assembly Resolution on Technical assistance provided by the United Nations Office
on Drugs and Crime related to counter-terrorism A/RES/74/175

Further, the UNODC is mandated to:

 Support Member States in addressing drug control, crime prevention, and criminal
justice.
 Promote adherence to international conventions on narcotics, corruption, and
organized crime.
 Enhance cooperation between countries in combating transnational threats.
 Provide technical assistance and research to help governments formulate evidence-
based policy.
 Ensure legal and ethical standards are maintained in justice systems globally.

5
 About the Agenda

The opioid crisis refers to the widespread misuse of both prescription and non-prescription
opioid drugs, leading to millions of addiction cases and hundreds of thousands of overdose
deaths globally. While opioids were originally developed for pain relief, aggressive
marketing, overprescription, and inadequate regulation—particularly in developing nations—
have contributed to a public health disaster.
This agenda offers a mixture of public health, corporate ethics, criminal justice, and
international law.
Key Facts

 The term “opioids” includes compounds that are extracted from the poppy
plant (Papaver somniferum) as well as semisynthetic and synthetic compounds with
similar properties that can interact with opioid receptors in the brain.
 Opioids are commonly used for the treatment of pain, and include medicines such as
morphine, fentanyl and tramadol.
 Their non-medical use, prolonged use, misuse and use without medical supervision
can lead to opioid dependence and other health problems.
 Due to their pharmacological effects, opioids can cause breathing difficulties, and
opioid overdose can lead to death.
 Worldwide, in 2019 about 600 000 deaths were attributable to drug use. Close to 80%
of these deaths are related to opioids, with about 25% of those deaths caused by
opioid overdose.
 There are effective treatment interventions for opioid dependence that can decrease
the risk of overdose, yet less than 10% of people who need such treatment are
receiving it.
Understanding the Nature of the Crisis
The opioid crisis is a multifaceted global emergency rooted in medical dependency, legal
loopholes, and ethical failings. To effectively respond to this crisis, it is critical to examine
the complexity of the crisis through multiple criteria’s.
Key Medical Concerns:
 Tolerance and Dependency: Patients often build resistance to opioids, requiring higher
doses, which increases the risk of dependence.
 Addiction and Overdose: Long-term opioid use can quickly escalate to addiction.
Synthetic opioids like fentanyl are especially potent and have caused a surge in
accidental overdose deaths.
 Lack of Alternatives: In many healthcare systems, especially in rural or underfunded
areas, opioids are often the only available or affordable pain relief, further
perpetuating dependency.

6
  Global Spread: Initially concentrated in high-income countries, the crisis is now
spreading to developing countries due to globalized pharmaceutical trade and lax
monitoring.
Key Legal Dimensions:
 Regulatory Loopholes: Companies have exploited weaknesses in drug approval
systems, securing licenses based on incomplete or manipulated clinical trials.
 Weak Monitoring Systems: Many countries lack systems to monitor opioid
prescriptions, enabling the diversion of legal drugs into black markets.
 Corporate Immunity: Pharmaceutical giants often used their legal resources to avoid
liability, delay lawsuits, or negotiate settlements without meaningful change.
 Lack of Global Consensus: International law has struggled to define the legal
obligations of private actors within transnational drug crime frameworks.
 State Involvement or Negligence: In some cases, governments failed to act despite
clear evidence, due to influence from pharmaceutical lobbies.
Key Ethical Dimension:
 Profit over People: Major companies knowingly downplayed the addictive nature of
opioids to expand their market and increase profits.
 Manipulation of Data: Scientific research was misrepresented or selectively published
to avoid highlighting the dangers of prolonged opioid use.
 Targeting Vulnerable Populations: Communities with lower education, limited
healthcare access, or high rates of manual labor were disproportionately targeted in
opioid marketing campaigns.
 Breach of Medical Ethics: Some doctors overprescribed opioids, motivated by
incentives from pharmaceutical reps or poor awareness of addiction risks.
 Lack of Remorse or Restitution: Even after lawsuits, many companies refused to
accept moral responsibility or offer adequate reparations to victims and communities.

Role of Pharmaceutical Corporations

Pharmaceutical corporations have played a very controversial role in the evolution of this
crisis. While these companies were originally tasked with developing life-saving pain
medications, their pursuit of profit, aggressive marketing practices, and disregard for public
health consequences significantly contributed to the widespread misuse and addiction
associated with opioids for all.

1. Overproduction and Distribution

Pharmaceutical corporations played a significant role in overproducing opioid medications,
manufacturing quantities that far exceeded the legitimate medical need. By exploiting weak
international and national regulatory controls, companies flooded markets with potent opioids
like oxycodone, fentanyl, and hydrocodone. In many instances, supply chains lacked
adequate oversight, allowing for large-scale diversion of these drugs into black markets. This

7
saturation, especially in underserved and rural areas, laid the groundwork for mass addiction
and widespread misuse, often without accountability or intervention.

2. Aggressive and Misleading Marketing

One of the most damaging strategies employed by pharmaceutical giants was their aggressive
and often deceptive marketing of opioids. Companies promoted opioids as safe and non-
addictive, deliberately downplaying risks while overstating benefits. They targeted physicians
with incentives, sponsored medical education programs that presented biased information,
and used direct marketing to encourage overprescription. Vulnerable populations, especially
in regions with poor access to alternative treatments, were heavily targeted, creating a cycle
of dependency under the guise of medical care.

3. Lobbying and Legal Manipulation

Pharmaceutical companies invested vast resources into lobbying efforts that stalled or
prevented regulatory reform. These firms influenced lawmakers to avoid classifying opioids
as high-risk drugs and to delay the implementation of national monitoring systems for
prescriptions. In addition, they used complex legal strategies to avoid criminal charges, delay
litigation processes, and negotiate settlements without admitting fault. Their lobbying not
only weakened institutional checks but also enabled continued profits at the expense of public
health and legal justice.

4. Data Suppression and Clinical Misconduct

A major ethical and legal violation committed by several pharmaceutical companies involved
the manipulation and suppression of clinical trial data. Firms often withheld negative
findings, published ghostwritten studies, and cherry-picked results to present opioids as safe
and effective. These fraudulent practices misled doctors, regulatory agencies, and even
medical journals, resulting in widespread prescription of opioids based on distorted evidence.
This deliberate misinformation compromised scientific integrity and directly contributed to
the mismanagement of pain relief treatments worldwide.

5. Negligence Toward Global Consequences

While the opioid crisis initially emerged in North America, pharmaceutical corporations
quickly extended their operations into less regulated regions, including parts of Asia, Latin
America, and Africa. In doing so, they capitalized on weak regulatory frameworks and poor
public health infrastructure to promote opioid use. Despite growing international concern,
these companies largely failed to account for the long-term public health risks in these
emerging markets. Their inaction allowed the crisis to become a global issue, with rising
addiction rates in countries previously unaffected.

8
6. Role in Recovery and Restitution (Post-Crisis)
In response to mounting public and legal pressure, several pharmaceutical corporations have
since taken steps toward restitution—but these efforts are often seen as insufficient or
strategically self-serving. Companies have declared bankruptcy and paid large settlements,
while others contributed to addiction recovery programs under legal compulsion. However,
these gestures came only after irreversible harm was done, and many critics argue that they
lacked genuine accountability. The post-crisis actions of these firms highlight the need for
systemic reform in corporate responsibility and transparency.

Influence on Prescription Practices

Pharmaceutical corporations have had a profound and often detrimental impact on global
prescription practices, particularly in how opioids were prescribed, promoted, and perceived
by the medical community. Their influence reshaped pain management standards and
contributed significantly to the normalization of long-term opioid use for chronic, non-cancer
pain—an approach that defied earlier medical caution.
One of the primary strategies used was the targeted marketing of opioids to healthcare
professionals, convincing them that these drugs were not only effective but also safe for
extended use. Pharmaceutical sales representatives offered incentives, bonuses, and funded
educational seminars to promote specific brands like OxyContin and Fentora, often
minimizing the risks of addiction. These campaigns framed opioids as essential tools in
modern pain relief, leading to a sharp rise in prescriptions, even for minor conditions.
Companies also sponsored research, continuing medical education (CME) programs, and
professional associations, which created an illusion of scientific consensus on the safety of
opioids. Doctors were encouraged to assess pain as the "fifth vital sign," and failure to treat
pain aggressively was increasingly viewed as medical negligence—further reinforcing the
role of opioids in clinical care. In some cases, corporate-funded guidelines were adopted into
national healthcare protocols, subtly shifting clinical norms in favor of opioid use.
This influence was particularly harmful in regions with low medical literacy or limited
regulatory oversight, where prescribers lacked access to unbiased data and often relied on
pharmaceutical information. The result was a widespread pattern of overprescription, misuse,
and dependency—laying the foundation for the current opioid crisis.
In short, pharmaceutical corporations manipulated both the supply side (by promoting mass
production) and the demand side (by shaping physician behavior), making prescription
practices a key driver of opioid addiction globally.

9
 International Actions & Legal Frameworks

1. International Drug Control Conventions

 Single Convention on Narcotic Drugs (1961)

Establishes international control over the cultivation, production, distribution, and trade of
narcotic drugs, including opioids. It requires member states to ensure that opioids are used
exclusively for medical and scientific purposes.
 Convention on Psychotropic Substances (1971)
Introduces controls over newer synthetic drugs, such as fentanyl analogues and other lab-
produced opioids.
 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic
Substances (1988)
Calls for stronger criminal justice responses to drug trafficking, including monitoring
pharmaceutical precursors and combating corporate-facilitated diversion.

2. UNODC and WHO Joint Initiatives

 The UN Toolkit on Synthetic Drugs

A resource for countries to identify gaps in regulation, enforce better prescription monitoring,
and control synthetic opioids.
 INCB’s Global OPIOIDS Control Framework
Oversees the trade and quotas of narcotic substances and promotes responsible prescribing
practices.
 Joint Task Forces
Supporting cross-border intelligence sharing to disrupt illegal pharmaceutical supply chains.

10
 Challenges in Global Regulation
1. Lack of Binding International Corporate Accountability
One of the core challenges is the absence of binding international legal mechanisms to hold
pharmaceutical corporations accountable for unethical practices. While treaties like the UN
Drug Conventions regulate narcotic substances, they focus primarily on state responsibilities
and criminal enterprises, not on private sector actors. There is no enforceable international
body to penalize corporations for aggressive marketing, overproduction, or misrepresentation
of medical data.
2. Weak and Uneven National Enforcement
Enforcement capacities vary greatly between countries. High-income nations may have
sophisticated monitoring systems and regulatory authorities, but many developing and low-
income countries lack robust frameworks, manpower, or political will to control
pharmaceutical practices. This inconsistency allows corporations to exploit regulatory gaps
and push opioids into poorly governed markets, often without consequences.
3. Influence of Pharmaceutical Lobbies
Powerful corporate lobbying groups significantly influence drug policy across the world. In
many countries, pharmaceutical giants spend millions lobbying governments to prevent
regulation, delay investigations, and weaken public health protections. This not only obstructs
reform but also undermines the independence of regulatory agencies.
4. Fragmented Data and Prescription Monitoring
A major barrier to effective regulation is the lack of standardized and shared international
data on opioid production, sales, and prescriptions. Most countries do not participate in a
centralized prescription monitoring system, and where such systems do exist, data is often
proprietary, outdated, or inaccessible. This limits the ability of authorities to detect
overprescription, diversion, or cross-border trafficking of legal opioids.
5. Legal Jurisdiction Issues
Pharmaceutical companies operate transnationally, while most legal systems are limited by
national jurisdiction. This creates difficulties in prosecuting corporations whose harmful
practices in one country are planned or executed from another. Cross-border legal
cooperation remains weak, and extradition treaties often do not cover corporate executives or
commercial offenses, limiting accountability.
6. Balancing Regulation with Medical Access
There is a persistent dilemma in global regulation: how to prevent opioid abuse while
ensuring access to essential pain medication for patients in need, especially in humanitarian
settings. Over-regulation can lead to opioid shortages in countries where they are legitimately
needed, while under-regulation fuels abuse. Striking this balance is a critical challenge in
creating effective, ethical policy.

7. Political Reluctance and Diplomatic Sensitivity

11
Many states are reluctant to confront major pharmaceutical companies due to economic
interests, foreign investment, or diplomatic ties. This hesitancy is especially evident in
countries where such corporations contribute significantly to national economies.
Furthermore, discussions around drug policies can be politically sensitive, often involving
blame-shifting rather than cooperation.

Role of UNODC and International Cooperation

1. Policy Leadership and Norm-Setting
The UNODC serves as a global policy leader by setting international norms and guidelines
related to drug control and regulation. Through its annual World Drug Reports, technical
publications, and recommendations, the UNODC promotes evidence-based, balanced
approaches that reduce drug misuse while ensuring access to essential medications. It
encourages member states to adopt policies that regulate opioid production, monitor
corporate behavior, and prevent the over-prescription of addictive substances—framing
global standards for both public health protection and pharmaceutical accountability.
2. Capacity Building and Technical Assistance
A core strength of the UNODC lies in its role as a technical advisor, especially in countries
with weak legal and health infrastructures. The agency offers capacity-building programs to
support the development of regulatory systems, prescription monitoring tools, forensic
capabilities, and criminal justice procedures. By training healthcare professionals, customs
officers, and legal experts, the UNODC empowers states to recognize, prevent, and prosecute
pharmaceutical malpractices that contribute to opioid misuse and trafficking.
3. Promoting Data Transparency and Early Warning Systems
To respond to emerging drug threats in real time, the UNODC facilitates global data-sharing
mechanisms such as the Global SMART Programme and early warning systems for new
psychoactive substances. These tools allow member states to detect patterns in opioid
prescriptions, monitor the global movement of synthetic opioids like fentanyl, and respond
swiftly to unusual drug-related incidents. Transparent data collection and dissemination are
essential for identifying and curbing both legal and illegal channels of pharmaceutical
distribution.
4. Facilitating Legal Cooperation and Anti-Corruption Efforts
UNODC plays a vital role in fostering cross-border legal cooperation, particularly in tackling
the corporate corruption and lobbying that has fueled the opioid crisis. By promoting
implementation of the UN Convention Against Corruption (UNCAC) and offering legal
expertise, the agency assists countries in drafting anti-corruption legislation, investigating
pharmaceutical lobbying efforts, and initiating mutual legal assistance treaties (MLATs) for
corporate accountability. This function helps build the international legal infrastructure
needed to pursue justice in transnational pharmaceutical crimes.

5. Multi-Agency Partnerships

12
Recognizing that the opioid crisis spans health, security, and legal domains, the UNODC
works collaboratively with key global agencies. With the World Health Organization (WHO),
it promotes safe prescribing practices; with Interpol and World Customs Organization
(WCO), it addresses illegal opioid trafficking; and with NGOs and civil society, it supports
addiction treatment and harm reduction programs. These multi-agency efforts ensure a
coordinated, holistic response that tackles the crisis from both preventive and punitive angles.
6. Promoting International Dialogue and Consensus
Through platforms like the Commission on Narcotic Drugs (CND) and global conferences,
the UNODC facilitates international dialogue, enabling countries to share experiences,
negotiate common standards, and commit to joint strategies. These forums allow states to
address regulatory gaps, discuss corporate accountability frameworks, and collaborate on
innovative policy solutions to the opioid crisis. By fostering such consensus, the UNODC
strengthens the global community’s collective ability to respond to the growing threat posed
by irresponsible pharmaceutical practices.

Key Terms and Definitions

Existing Terms from the Document
1. Opioid Crisis: A global public health emergency caused by the widespread misuse of
prescription and non-prescription opioids, leading to addiction, overdose deaths, and societal
harm.
2. UNODC: UN agency established in 1997 to combat drugs, crime, terrorism, and corruption
through international cooperation, policy guidance, and technical assistance.
3. Fentanyl: A highly potent synthetic opioid, 50–100 times stronger than morphine, often
illegally manufactured and linked to overdose deaths.
4. Prescription Monitoring Programs (PMPs): Government-run databases tracking controlled
substance prescriptions to prevent misuse and doctor shopping.
5. Diversion: The redirection of legally prescribed opioids to illegal markets, often due to lax
regulations or unethical practices.
6. Single Convention on Narcotic Drugs (1961): A treaty establishing international control
over narcotics, ensuring opioids are used only for medical and scientific purposes.
7. Corporate Lobbying: Efforts by pharmaceutical companies to influence legislation and
regulations in their favor, often delaying stricter opioid controls.
8. Harm Reduction: Policies and programs (e.g., naloxone distribution, supervised injection
sites) aimed at minimizing health risks for drug users.
9. Commission on Narcotic Drugs (CND): The UN policymaking body overseeing drug
control treaties and UNODC governance.

13
10. Overprescription: The excessive prescribing of opioids beyond medical necessity,
contributing to addiction and misuse.
Additional Relevant Key Terms
11. Opioid Use Disorder (OUD): A medical condition characterized by compulsive opioid use
despite harmful consequences.
12. Naloxone: A life-saving medication that reverses opioid overdoses by blocking opioid
receptors.
13. Drug Trafficking Networks: Organized criminal groups involved in the illegal production,
distribution, and sale of opioids.
14. Synthetic Opioids: Lab-made opioids (e.g., fentanyl, carfentanil) designed to mimic
natural opiates but often more dangerous.
15. Pain Management Alternatives: Non-opioid treatments (e.g., physical therapy, NSAIDs,
medical cannabis) for chronic pain to reduce reliance on opioids.
16. Stigmatization of Addiction: Societal prejudice against drug users, hindering access to
treatment and recovery support.
17. Extradition Treaties: Agreements between countries to surrender individuals accused of
crimes, relevant for prosecuting corporate executives in transnational cases.
18. Precursor Chemicals: Substances used to manufacture synthetic opioids, often smuggled
across borders.
19. Good Samaritan Laws: Legal protections for individuals seeking emergency help for
overdose victims, encouraging reporting without fear of prosecution.
20. Public Health Approach: A strategy focusing on prevention, education, and treatment
rather than punitive measures to address addiction.

Recommended Readings for Delegates

1. UNODC & WHO Reports
 UNODC World Drug Report (Latest Edition)
 Overview: Annual global analysis of drug trends, including opioids, trafficking, and
policy responses.
 ([Link]

 WHO Guidelines for the Pharmacological Treatment of Chronic Pain

 Overview: Evidence-based recommendations for opioid and non-opioid pain
management.
 ([Link]
 INCB (International Narcotics Control Board) Annual Report

14
  Overview: Monitors global opioid production quotas and compliance with drug
treaties.
 ([Link]

2. Pharmaceutical Industry & Corporate Accountability

 "Empire of Pain: The Secret History of the Sackler Dynasty" (Patrick Radden Keefe)
 Overview: Investigates Purdue Pharma’s role in the opioid crisis.
 Relevance: Corporate misconduct, lobbying, and legal evasion.
 [Summary]([Link]
patrick-radden-keefe/)

 "Pharmaceutical Fraud: Case Studies" (U.S. Department of Justice)

 Overview: Legal cases against opioid manufacturers for false marketing.
 ([Link]
criminal-and-civil-investigations-opioid)

3. Legal Frameworks & Treaties

 UN Convention Against Corruption (UNCAC)
 Overview: Key treaty for combating corporate corruption in pharmaceuticals.
 ([Link]

 The 1988 Drug Trafficking Convention

 Overview: Criminalizes diversion of legal opioids to illicit markets.
 ([Link]

4. Public Health & Harm Reduction

 CDC Guideline for Prescribing Opioids (U.S. Centers for Disease Control)
 Overview: Best practices to curb overprescription.
 ([Link]

 Global Commission on Drug Policy Reports

 Overview: Advocates for decriminalization and harm reduction (e.g., supervised
injection sites).
 ([Link]
5. Data & Monitoring Tools
 UNODC Synthetic Drugs Monitoring Toolkit

15
  Overview: Tracks fentanyl analogues and emerging opioids.
 ([Link]

 EMCDDA (European Monitoring Centre for Drugs and Drug Addiction)

 Overview: EU-focused opioid data, including prescription misuse.
 ([Link]

6. Ethical & Humanitarian Perspectives

 "The Right to Pain Relief: Balancing Access and Control" (Human Rights Watch)
 Overview: Tension between preventing abuse and ensuring pain treatment in low-
income countries.
 ([Link]
human-right)

 "Do No Harm: The Opioid Epidemic in the Global South" (The Lancet)
 Overview: Risks of opioid expansion in developing nations.
 ([Link]
fulltext)

16